Health consequences of cocaine use in France: data from the French Addictovigilance Network

Abstract

As the number and severity of complications related to cocaine use reported to the French Addictovigilance Network have increased, the French health authorities requested a national epidemiologic study of the data collected by this network from 2010 to 2016. For this purpose, the spontaneous reports (SRs) linked to cocaine notified by health professionals were analyzed as well as the data from the pharmacoepidemiological surveys OPPIDUM (observation of illegal drugs and misuse of psychotropic medications) and DRAMES (deaths related to the abuse of licit and illicit psychoactive substances). In total, 1 265 SRs were analyzed (510% increase from 2010 to 2016). Users were mainly men (952/1 261; 75%), with a median age of 35.0 years [IQ25–75: 28–42]. Cocaine was consumed through the intranasal route by 52% of users (416/797), followed by intravenous administration (32%, 253/797) and inhalation (24%, 190/797). The use of cocaine powder and crack cocaine was reported in 70% (475/674) and 23% (154/674) of SRs, respectively. Cocaine was consumed with other psychoactive substances and alcohol in 47% (603/1265) and 60% (387/649) of cases, respectively. The main cocaine‐related complications were psychiatric complications (29%), neurologic complications (24%) and cardiovascular complications (23%). Analysis of the OPPIDUM survey data showed that in 2016, 15.9 and 2.4% of the included subjects consumed cocaine or crack cocaine the week preceding the survey, the highest rate for the 2006–2016 period. The DRAMES survey indicated that cocaine‐related deaths increased by threefold from 2014 to 2016. These data confirm that cocaine use in France is worrying with an increase in the number of severe complications and deaths.

Discussed Poster Abstracts

“…Discussion/Conclusion: Our preclinical data show that the anti-arthritic effect of tofacitinib is coincident to favourable changes in mucosal immunity and gut microbiota [3]. References: [1] Hodge JA, et al The mechanism of action of tofacitinib -an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol.…”

“…Introduction: CCR3 is the receptor for Eotaxin, RANTES and other ligands and is considered as a potential therapeutic target in inflammatory bowel diseases (IBD) [1]. In this study, we investigated whether CCR3 deficiency or pharmacological blockade could be beneficial in an experimental model of colitis in mice.…”

“…Introduction: Tofacitinib is a potent and orally active inhibitor of the JAK family (with high selectivity to JAK-1 and JAK-3) that suppresses inflammatory signaling of γc-chain cytokines but also of IL-6 and interferon-γ [1]. It is the first in class targeted synthetic diseasemodifying antirheumatic drugs (tsDMARDs) for RA, whose indications have been extended recently to psoriatic arthritis and ulcerative colitis.…”

“…Autophagy being defective in osteoarthritis (OA), it is a pharmacological candidate (10μM) for experimental intra-articular (IA) OA treatment. As we previously developed rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles (NPs) [1] we compared in rats local and systemic rapamycin concentrations after knee IA injections of NPs vs. free formulation compared to intravenous (IV) administration of free rapamycin. Material and methods: Rats received a single free or NPs-loaded rapamycin injection in right knees (50 μL, 10 μM).…”

Doctor shopping for methylphenidate as a proxy for misuse and potential abuse in the 67 million inhabitants in France

“…Recreational use, abuse, and addiction constitute another set of risks related to the dopamine‐mediated psychostimulant profile of methylphenidate, in a similar way than illicit psychostimulants, such as cocaine [4]. Using nation‐wide data from the French national health data system, the team of Joëlle Micallef, Aix‐Marseille Université, France, has explored the profile of subjects with doctor‐shopping behavior for methylphenidate in the French population [5].…”